Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Ieyoub

Internal Medicine Lake Charles, LA Medical Doctor

NPI 1255404521 CMS profile 147948

4345 Nelson Rd Ste 201, Lake Charles, LA 70605

Open in the dashboard

General payments

$3,980

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Ieyoub of Lake Charles, LA is reported in the CMS Open Payments database as having received $3,980 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $339 18
2024 General $462 26
2023 General $987 29
2022 General $412 26
2021 General $636 48
2020 General $204 14
2019 General $940 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Ieyoub
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Susan Ieyoub were reported at $339. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Susan Ieyoub Internal Medicine median Middle half National median
2019 $940 $159 $48–$570 $163
2020 $204 $119 $33–$402 $114
2021 $636 $135 $37–$521 $132
2022 $412 $141 $42–$496 $149
2023 $987 $149 $45–$519 $160
2024 $462 $154 $47–$537 $164
2025 $339 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $615 41 payments
  2. GlaxoSmithKline, LLC. $486 21 payments
  3. TransMedics, Inc. $439 1 payment
  4. Pfizer Inc. $432 37 payments
  5. Novo Nordisk Inc $406 32 payments
  6. Lilly USA, LLC $207 13 payments
  7. Janssen Pharmaceuticals, Inc $157 13 payments
  8. Allergan Inc. $131 20 payments
  9. Amgen Inc. $128 8 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $123 6 payments
  11. Other $856 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,541 247 payments
  2. Travel and Lodging $439 1 payment
Products named General payments · program years 2019–2025
  1. ORGAN CARE SYSTEM $439 1 payment
  2. TRELEGY ELLIPTA $421 17 payments
  3. VRAYLAR $344 25 payments
  4. AREXVY $302 12 payments
  5. ELIQUIS $292 24 payments
  6. Ozempic $275 22 payments
  7. SHINGRIX $244 10 payments
  8. RYBELSUS $225 18 payments
  9. QULIPTA $161 8 payments
  10. XARELTO $157 13 payments
  11. Other $3,046 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 195 drugs

Part D claims

17,772

Median for Internal Medicine: 777

Drug cost

$1,019,396

Median for Internal Medicine: $73,373

Branded share of claims

17.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 136 $134,618
Mounjaro Tirzepatide Brand 109 $133,721
Eliquis Apixaban Brand 202 $101,539
Ingrezza Valbenazine Tosylate Brand 11 $88,464
Jardiance Empagliflozin Brand 179 $84,745
Xarelto Rivaroxaban Brand 49 $45,896
Farxiga Dapagliflozin Propanediol Brand 47 $32,654
Trulicity Dulaglutide Brand 25 $31,897
Linzess Linaclotide Brand 45 $31,814
Entresto Sacubitril/Valsartan Brand 31 $24,116

The 10 drugs with the highest cost, of 195 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$153,696

Of which drugs: $21,465

Medicare patients

543

Average age 78

Services billed

4,110

363 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 34%
Ischemic heart disease 31%
Depression 29%
Chronic kidney disease 27%
Alzheimer's or dementia 24%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 45 46 $13,279
Vaccine for influenza for injection into muscle 90662 Office 82 82 $6,432
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 48 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $53
$53 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $52
$52 13 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $40
$40 — —
AREXVY
  • GlaxoSmithKline, LLC. $40
$40 — —
Veozah
  • Astellas Pharma US Inc $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record